Argobio
PrivateLast Round
VC Round
Mar 2, 2021
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Argobio operates in Healthcare & Life Sciences and is based in France. Its latest recorded funding round was a VC Round in March 2021.
Argobio is a French start-up studio dedicated to life sciences that creates and develops biotech companies from early-stage scientific innovations. It sources projects from European academic research institutions, focusing on therapeutic areas such as rare diseases, neurological disorders, oncology, and immunology. Argobio incubates these projects, providing scientific, entrepreneurial, and financial support to build them into standalone companies and advance them to a significant Series A financing round. The studio was launched in March 2021 with €50 million in capital from a syndicate of investors including Kurma Partners, Bpifrance, Angelini Pharma, Evotec, and the Institut Pasteur.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Argobio Comparables
Compare Argobio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Remora Biotech | 83% | |
| AQYLA BioVentures | 83% | |
| Slingshot Therapeutics | 80% |
For institutional investors. Book with your work email.
Argobio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Argobio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Angelini Ventures | VC Round |
| Institut Pasteur | VC Round |
| Bpifrance | VC Round |
| Kurma Partners | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 125% MoM, reaching 1.4K.
- Apr 18, 2026
Monthly visitors grew 381% MoM, from 420 to 2K.
For institutional investors. Book with your work email.
Argobio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Argobio's valuation, stock price, and market status.
Is Argobio a public or private company?
Argobio is a private company.
What is the current stock price of Argobio?
Argobio is a private company, so its shares have no public market price. Caplight tracks Argobio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Argobio worth (valuation)?
Valuation information for Argobio is not publicly available.
Can I buy Argobio stock?
Argobio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Argobio's last funding round?
Argobio's most recent funding round was VC Round on March 2, 2021.
Who are the main investors in Argobio?
Key investors in Argobio include Kurma Partners.
Will Argobio IPO soon?
No public IPO plans have been announced for Argobio.
How can I track Argobio secondary market activity?
Caplight tracks bids, offers, and trades in Argobio's shares on secondary markets.